SureSeq myPanel™ NGS Custom Cancer Panels
A regularly updated, expert-curated library of pre-optimised cancer panel content for you to select from. Simply mix and match the gene, exonic or intronic content you need to create an NGS cancer panel that meets your exact requirements.
SureSeq myPanel offers:
- Hybridisation-based panel delivering unparalleled coverage uniformity — detect low-frequency variants consistently with confidence and minimise the requirement for supplementary fill-in with Sanger sequencing
- Pre-optimised panels that meet your technical requirements and work with your samples (including FFPE tissue) — no more laborious in-house optimisation, decreasing assay development time
- Bespoke panel content — sequence only what’s relevant for your cancer research, increase throughput and save on sequencing reagents
- Panel content designed with experts and from current literature to target all relevant regions including intronic and splice sites — get the most comprehensive insight into disease-driving mutations
Tired of paying to sequence genes you’re not interested in? Then don’t!
Simply select the gene, exonic or intronic content you need from Oxford Gene Technology’s (OGT) regularly updated, expert-curated library of pre-optimised cancer panel content. Our unique panel design coupled with hybridisation-based enrichment offers unparalleled coverage completeness and uniformity. This allows the accurate detection of difficult to sequence, low-frequency variants and minimises the requirement for supplementary fill-in with Sanger sequencing.
myPanel — Excellent coverage of “difficult” genes
Figure 1: Accurate detection of difficult to sequence genes. Mutations in the CEBPA gene are among the most common molecular alterations in AML and bear important significance. Sequencing of the CEBPA gene is often hampered by a repetitive nucleotide sequence and a high GC-rich content, which can lead to technical challenges in assay design, requiring a supplementary fill-in with Sanger sequencing. OGT’s expert bait design overcomes these issues, offer a high level of uniformity coverage for a notoriously difficult gene to sequence.
myPanel — Don’t miss critical variants
Figure 2: Sensitive detection of critical variants. The CALR gene is commonly mutated in various myeloproliferative neoplasms (MPNs). It is critical to identify key CALR indels (types 1 and 2 causing a frameshift) as well as increasingly recognised point mutations in this gene. OGT’s expert bait design offers excellent coverage uniformity across low-complexity regions with low nucleotide diversity (such as CALR exon 9), compared to other commercially available bait designs, which suffer from a considerable dip in coverage.
BCR-ABL Fusion gene
Figure 3. The BCR/ABL translocation is commonly known as the Philadelphia translocation and occurs when the ABL1 (Abelson) proto-oncogene and the BCR (Breakpoint Cluster Region) gene fuse. In this example, two translocations are present, with both BCR-ABL1 (chr11:23,632,850/chr9:133,643,198) and ABL1-BCR (chr9:133,643,072/chr22:23,632,613) translocations identified in the CML cell line JK-1. The breakpoints identified by NGS were found to match the coordinates reported in the literature1.
SureSample is a set of 44 single nucleotide polymorphisms (SNPs) to add to your SureSeq myPanel custom NGS panel to assist in sample identification. Throughout the library preparation process, they provide reliable sample tracking and easy identification of sample mix-up.
Whilst good practice in the handling of samples and increased laboratory automation minimises potential for error, additional checkpoints are valuable, particularly where multiple processing steps necessitate transfer of samples between different facilities.
The 44 SNPs selected have a minor allele frequency of 45-55% across six major HapMap populations, these 44 SNPs afford 88 points of allelic comparison providing highly discriminatory identifiers giving a likelihood of 1 in 5.6814 of two random samples having identical SNP profiles (Figure 4).
Figure 4. Integrated Genomics Viewer image comparing the profiles from 9 samples over 8 of the 44 SNPs in the SureSample panel, illustrating how the SNP profiles differ from sample to sample.
- Confidence in results - SureSample provides an additional checkpoint valuable in supporting laboratory quality control
- Reliable identification of sample mix-up - Maintain data integrity and sample provenance
Add SureSample to your next SureSeq custom panel.
myPanel — Customise the following panels:
|Solid Tumour Panels||Gene List|
|Breast cancer||View gene list|
|Colorectal||View gene list|
|Glioma||View gene list|
|Lung Cancer||View gene list|
|Ovarian Cancer||View gene list
|Melanoma||View gene list|
|Prostate Cancer||View gene list|
|Sarcoma||View gene list|
|Haematology Panels||Gene List|
|AML||View gene list|
|CLL||View gene list|
|CML||View gene list|
|Core MPN||View gene list|
|MPN/MDS overlap||View gene list|
|Myeloid||View gene list|
myPanel — Other Panels
|SureSeq myPanel Custom Myeloid Panel - 49 gene plus||View gene list|
|SureSeq myPanel Custom Myeloid Panel - 49 gene||View gene list|
|SureSeq myPanel Custom Myeloid Panel - 27 gene||View gene list|
|SureSeq myPanel Custom Core MPN Panel - 5 exon||View gene list|
|SureSeq myPanel Custom CLL Panel – 14 gene||View gene list|
|SureSeq my Panel Custom panel - BRCA1 & BRCA2||View gene list|
|SureSeq my Panel Custom panel – ATM||View gene list|
|SureSeq my Panel Custom panel – TP53||View gene list|
|SureSeq myPanel Custom Core AML Panel - 2 gene||View gene list|
Can't see a panel that exactly meets your requirements, let us know the genes you are interested in and we'll create it.
We were delighted with the performance of the SureSeq panel. It showed complete concordance with our other techniques, detecting all known mutations with excellent sensitivity down to 1% [MAF (minor allele frequency)], including, in one case, a JAK2 V617F mutation which was not detected by ddPCR due to a second mutation under the primer. The panel also demonstrated mutations in other genes in samples with low level JAK2 V617F and good correlation between allele frequencies and quantitative analysis by ddPCR. We are planning to adopt the panel in the near future." Dr Anna Skowronska, R&D Scientist, Haemato-Oncology team, West Midlands Regional Genetics Laboratory (WMRGL) of the Birmingham Women’s NHS Foundation Trust, UK
Getting started with your next SureSeq myPanel Custom Cancer Panel could not be simpler...
Let us know your cancer(s) of interest and allow OGT to put our expertise to work in advancing your cancer research.
|SureSeq myPanel NGS Custom Cancer Panels||Enrichment baits; SureSeq Interpret Software||various||Get a quote|
|SureSeq myPanel Custom Myeloid Panel - 49 gene plus||Enrichment baits; SureSeq Interpret Software||
602017-16 (16 reactions)
602017-96 (96 reactions)
|Get a quote|
|SureSeq myPanel Custom Myeloid Panel - 49 gene||Enrichment baits; SureSeq Interpret Software||
602008-16 (16 reactions)
602008-96 (96 reactions)
|Get a quote|
|SureSeq myPanel Custom Myeloid Panel - 27 gene||Enrichment baits; SureSeq Interpret Software||
602009-16 (16 reactions)
602009-96 (96 reactions)
|Get a quote|
|SureSeq myPanel Custom Core MPN Panel - 5 exon||Enrichment baits; SureSeq Interpret Software||
602005-16 (16 reactions)
602005-96 (96 reactions)
|Get a quote|
|SureSeq myPanel Custom CLL Panel – 14 gene||Enrichment baits; SureSeq Interpret Software||
602013-16 (16 reactions)
602013-96 (96 reactions)
|Get a quote|
|SureSeq my Panel Custom panel – BRCA1 & BRCA2||Enrichment baits; SureSeq Interpret Software||
602011-16 (16 reactions)
602011-96 (96 reactions)
|Get a quote|
|SureSeq my Panel Custom panel – ATM||Enrichment baits; SureSeq Interpret Software||
602010-16 (16 reactions)
602010-96 (96 reactions)
|Get a quote|
|SureSeq my Panel Custom panel – TP53||Enrichment baits; SureSeq Interpret Software||
602012-16 (16 reactions)
602012-96 (96 reactions)
|Get a quote|
|SureSeq myPanel Custom Core AML Panel - 2 gene||Enrichment baits; SureSeq Interpret Software||
602006-16 (16 reactions)
602006-96 (96 reactions)
|Get a quote|
|Sure Seq FFPE DNA Repair Mix (16 reactions)||Enzyme mix and buffer sufficient for 16 FFPE DNA samples||500079||Get a quote|
|SureSeq NGS Library Preparation Kit (16)||Bundle of 1 x library preparation kit (16) containing adaptors, PCR primers and enzymes sufficient for 16 samples and 1 x SureSeq NGS Index Kit – Collection A||500070||Get a quote|
|SureSeq NGS Library Preparation Kit (48)||Bundle of 3 x library preparation kit (16), containing adaptors, PCR primers and enzymes sufficient for 48 samples and 1 x SureSeq NGS Index Kit – Collection B||500073||Get a quote|
|SureSeq NGS Index Kit - Collection A (16)||16 different indexes, each sufficient for 4 samples [included with SureSeq NGS Library Preparation Kit (16)]||500071||Get a quote|
|SureSeq NGS Index Kit - Collection B (48)||48 different indexes, each sufficient for 4 samples [included with SureSeq NGS Library Preparation Kit (48)]||500072||Get a quote|
|Dynabeads™ M270 Streptavidin, 2ml||Sample capture beads, sufficient for 20 samples||500080*||Get a quote|
|AMPure® XP beads, 10ml||Sample purification beads, sufficient for 16 samples||500081*||Get a quote|
* Only for use with SureSeq NGS panels
- Ross, David & Schafranek, Lisa & Hughes, Timothy & Nicola, Mario & Branford, Susan & Score, Joannah. (2009). Genomic translocation breakpoint sequences are conserved in BCR-ABL1 cell lines despite the presence of amplification. Cancer genetics and cytogenetics. 189. 138-9. 10.1016/j.cancergencyto.2008.10.010.
Evaluation of enzymatic DNA digestion as an alternative to mechanical DNA fragmentation (sonication) for targeted NGS using the SureSeq™ Myeloid Panel
DNA fragmentation is a crucial first step in the preparation of libraries for NGS. In this application note, Oxford Gene Technology has evaluated an alternative method of fragmentation using the NEBNext® dsDNA Fragmentase®.
Improving experimental reproducibility through automated hybridisation-based NGS library preparation
In this application note, an Agilent Bravo A Automated Liquid Handling Platform was configured to run the SureSeq NGS library preparation protocol. The results demonstrate marked improvement not only in hands-on-time, but also a number of quality metrics
Selecting the best NGS enrichment assay for your needs
With NGS now in routine use for a broad range of research and clinical applications, this application note details the value of making the correct choice for the initial sequence enrichment step.
SureSeq myPanel™ NGS Custom AML Panels
SureSeq myPanel™ NGS Custom Breast Cancer panel
SureSeq myPanel™ NGS Custom Cancer Panels
SureSeq myPanel™ NGS Custom Colorectal Cancer Panel
SureSeq myPanel™ NGS Custom Melanoma Cancer Panel
SureSeq myPanel™ NGS Custom Prostate Cancer Panel
SureSeq™ FFPE DNA Repair Mix
SureSeq™ NGS Library Preparation Kit
SureSeq myPanel™ NGS Custom Cancer Panels Full Gene List
We now have 120 genes available for our SureSeq myPanel NGS Custom Cancer Panels. View and download a complete list of available cancer gene content.
The role of NGS in stratified cancer medicine
In this white paper, two Clinical Scientists, Dr Matthew Smith and Dr George Burghel, share their views on the use of NGS in cancer genomics and its integration into the laboratory.
Understanding myeloid disorders with next-generation sequencing
How OGT’s SureSeq™ Myeloid Panel helps researchers identify and decipher the complex genetic origins of myeloproliferative disorders
Assessment of the performance of a hybridisation-based NGS enrichment panel with as little as 10 ng of severely formalin-compromised DNA
Presented at AMP 2018, this poster illustrates the excellent performance of a hybridisation-based NGS enrichment panel, in conjunction with an FFPE repair mix.
Beyond FISH, SNVs and indels – improved resolution of translocation detection using next generation sequencing (NGS)
Presented at AMP 2018, this poster demonstrates how the superior uniformity of coverage of the hybridisation-based approach of the SureSeq™ protocol in combination with a SureSeq myPanel™ NGS Custom panel reliably detects somatic BCR-ABL1 translocations.
Optimised, 1-day hybridisation-based NGS protocol yields 1% variant detection in MPN samples, as quickly and cost-effectively as multiplex PCR
Presented at AMP 2016, this poster outlines how the SureSeq™ Core MPN Panel can accurately detect alleles down to 1% variant allele fraction (VAF) in JAK2 (V617F) at a read depth of >1000x, facilitating reliable detection.
The accurate detection by next-generation sequencing (NGS) of difficult to sequence genes (CALR, CEBPA, FLT3) associated with myeloid disorders using a hybridisation-based enrichment approach
Presented at CGC 2017, this poster highlights the excellent uniformity of coverage obtained from the hybridisation-based enrichment using the SureSeq myPanel NGS Custom AML Panel.
The analysis of myeloproliferative neoplasm samples using a rapid (30 minute) hybridisation-based enrichment protocol for next-generation sequencing (NGS)
Presented at the CGC 2017 annual summer meeting in Denver, USA, this poster illustrates the excellent quality data generated by the OGT 1-day hybridisation-based SureSeq LPK protocol in combination with the SureSeq Core MPN Panel.
The application of a hybridisation-based next-generation sequencing (NGS) enrichment panel for the analysis of key genes involved in ovarian and breast tumours using DNA from FFPE samples
The application of a hybridisation-based NGS enrichment panel for the analysis of somatic variants in tumour samples and reference standards
Presented at AGT 2017, this poster outlines the application of a hybridisation-based NGS enrichment panel for the analysis of solid tumour somatic variants, demonstrating 100% concordance in variant detection in both genomic and formalin-compromised DNA.
The application of a one-day hybridisation-based enrichment protocol for NGS incorporating a rapid (30 minute) hybridisation step
Presented at AGT 2017, this poster outlines how OGT has optimised a one-day hybridisation-based enrichment protocol for NGS incorporating a rapid 30 hybridisation step.
The use of a hybridisation-based NGS enrichment panel for the confident identification of a broad range of low frequency variants from as little as 50ng of challenging clinical research FFPE samples
Presented at AMP 2016, this poster outlines how the SureSeq FFPE DNA Repair Mix significantly improves NGS library yields, with an increase of mean target coverage (increased by >2.2 fold), resulting in more meaningful data.